No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BEAM240719C25000
- 2.05
- 0.000.00%
15min DelayClose Jul 18 15:59 ET
2.05High2.05Low
2.05Open2.05Pre Close1 Volume191 Open Interest25.00Strike Price205.00Turnover223.99%IV6.25%PremiumJul 19, 2024Expiry Date0.46Intrinsic Value100Multiplier1DDays to Expiry1.59Extrinsic Value100Contract SizeAmericanOptions Type0.5819Delta0.1182Gamma16.43Leverage Ratio-0.7308Theta0.0004Rho9.56Eff Leverage0.0058Vega
Intraday
- 5D
- Daily
News
Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines
J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $45
J.P. Morgan analyst Eric Joseph maintains $Beam Therapeutics(BEAM.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 50.3%
Beam Therapeutics Shares Fall After News of CFO Departure
By Zaeem Shoaib Beam Therapeutics shares fell Monday after the company said its finance chief would be leaving the company in August. Shares were down 8.8% to $24.52 in recent afternoon trading, and
Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will
Beam Therapeutics Has Initiated a Search for a Successor >BEAM
Beam Therapeutics Has Initiated a Search for a Successor >
Express News | Beam Therapeutics Inc - CFO Terry-Ann Burrell to Leave August 9, 2024
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
$Beam Therapeutics(BEAM.US$ Will double to 90 dollars 💸 💵 💲
1
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
Beam Therapeutics' CEO, John Evans showed confidence in Ms. Shaw's ability to turn scientific innovations into commercial treatments. Shaw recognizes Beam's groundbreaking work in genetic medicine and gene editing, predicting major clinical milestones ahead thanks to the company's comprehensive platform and capabilities.
Read more